1. 2504 Genomic predictive and prognostic factors from plasma cell-free DNA (cfDNA) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) commencing enzalutamide (ENZ). (September 2015) Authors: Chi, K.; Azad, A.; Volik, S.; Haegert, A.; Zalcberg, J.; Le Bihan, S.; McConeghy, B.; Gleave, M.; Wyatt, A.; Collins, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis. (September 2015) Authors: Aviles, C.M.; Azad, A.A.; Todenhöfer, T.; Eigl, B.J.; Kollmannsberger, C.; Murray, N.; Chi, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC). (September 2015) Authors: Chi, K.; Castellano, D.; De Bono, J.; Gravis, G.; Dirix, L.; Machiels, J.P.; Mita, A.; Mellado Gonzalez, B.; Massard, C.; Trandafir, L.; Dey, D.; Csonka, D.; Chakravartty, A.; Fizazi, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen. (September 2015) Authors: De Bono, J.; Higano, C.; Blumenstein, B.; Feyerabend, S.; Gravis, G.; Ferrero, J.M.; Jacobs, C.; Chi, K. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EP-1359: Pain response in a Population-based study of Radium-223 for Metastatic Prostate Cancer. (May 2017) Authors: Tyldesley, S.; Parimi, S.; Tsang, E.; Bachand, F.; Aparicio, M.; Duncan, G.; Sunderland, K.; Olson, R.; Pai, H.; Alexander, A.; Lapointe, V.; Chi, K. Journal: Radiotherapy and oncology Issue: Volume 123:(2017:May)Supplement 1 Page Start: S729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗